| Corporate Name |
 |
Y's Therapeutics Co., Limited |
| Paid-in Capital |
|
¥3,340 million (¥6,654 million including capital reserves) |
| Business Field |
|
Research and development of pharmaceutical products |
| Number of Staffs |
|
34 (including related company) July 7, 2008 |
| Address |
|
Fujiwara Building, 4F
1-10-11 Ebisu-Nishi, Shibuya-ku, Tokyo 150-0021
 Access Map |
| Address |
|
866 Malcolm Road, Burlingame, CA 94010, USA |
| Mar. 2003 |
|
Established in Tokyo as a biopharmaceutical company engaged in the research and development of biological drugs, small molecule compounds, and dietary supplements |
| Jul. 2003 |
|
Obtained the rights to apply for patents for YSTH2 and YSTOP projects from TOUDAl TLO, Ltd. |
| May 2004 |
|
Established Y's Therapeutics, Inc.（California, USA） |
| Sep. 2004 |
|
Granted Kissei Pharmaceutical Co., Ltd. the right of first refusal to an exclusive license in Japan for commercialization of YSCMA |
| Oct. 2004 |
|
Established Y's Therapeutics GmbH (Neuss, Germany) |
| Feb. 2005 |
|
Initiation of laboratory facility at Y's Therapeutics, Inc. |
| Jun. 2005 |
|
Asset Purchase Agreement with US biotechnology company on disposition of YSPSL project |
| Jul. 2005 |
|
Patent and Technology License Agreement with The University of Texas M.D. Anderson Cancer Center and Dana-Farber Institute, Inc. on YSCMA project |
| Jul. 2006 |
|
Y’s Therapeutics Clinical-Stage Compound YSPSL Granted Orphan Status in U.S. and Europe
for the prevention of Delayed Graft Function in Kidney transplantation |
| Aug. 2007 |
|
Y’s Therapeutics Clinical-Stage Compound YSPSL Granted Orphan Status in U.S. for
the prevention of Ischemia Reperfusion Injury in transplantation of all organs |
| Jan. 2008 |
|
Closed Y's Therapeutics GmbH (Neuss, Germany) |
| Feb. 2008 |
|
Y's Therapeutics Initiated Phase I Clinical Program to Evaluate
YSCMA in U.S. |
